Multicenter trial to evaluate the safety and potential efficacy of pooled human fibrin sealant for the treatment of burn wounds.

OBJECTIVE The primary purpose of this multicenter study was to evaluate the safety and potential efficacy of a solvent/detergent-treated commercial fibrin sealant (human) for topical hemostasis in skin grafting. METHODS The study involved a prospective evaluation of changes in viral titers in patients with burns less than 15% after treatment with fibrin sealant (human). Each patient served as his/her own control for an unblinded, randomized comparison of donor site hemostasis and healing. Preoperative serum was obtained to screen for viral titers. At autografting, the recipient site and one of two randomly chosen donor sites were treated with fibrin sealant (human). The use of other hemostatic agents, including epinephrine was prohibited. Each donor site was covered with gauze to collect blood for estimation of the relative amount of bleeding. The healing of the graft and donor sites was observed. Viral titers and wounds were checked monthly for 6 months, and at 9 and 12 months postoperatively. RESULTS Viral titers for human immunodeficiency virus; hepatitis A, B, and C; Epstein-Barr virus; and cytomegalovirus were obtained before and after treatment. Of 47 patients, 34 completed the full year of observation. After treatment, there were no seroconversions to any of the aforementioned viruses. Bleeding at the recipient site appeared well controlled with fibrin sealant (human). Although investigators felt that fibrin sealant (human) improved donor site hemostasis, differences in hemoglobin measurements of blood-soaked dressings failed to reach significance. No differences were noted with regard to acceleration of donor site healing, graft take, or scar maturation at the two groups of donor sites. Anecdotally, the maturation of the recipient site appeared to be accelerated. CONCLUSION Fibrin sealant (human) is safe for use during excision and grafting, and its topical hemostatic potential needs to be examined in patients with larger burns. Its role in scar maturation also needs to be investigated.

[1]  J. Black,et al.  Development of a factor V and thrombin inhibitor following partial hepatic resection and the use of topical thrombin concentrate. , 2008, Clinical and laboratory haematology.

[2]  R. Bartlett,et al.  Prospective, randomized evaluation of the efficacy of fibrin sealant as a topical hemostatic agent at the cannulation site in neonates undergoing extracorporeal membrane oxygenation. , 1997, American journal of surgery.

[3]  G. Satten,et al.  Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. , 1995, The New England journal of medicine.

[4]  S. Schulman,et al.  Fibrin Sealant in Surgery of Patients with a Hemorrhagic Diathesis , 1995, Thrombosis and Haemostasis.

[5]  W. Spotnitz.  Fibrin Sealant in the United States: Clinical Use at the University of Virginia , 1995, Thrombosis and Haemostasis.

[6]  R. Shimizu,et al.  An anaphylactic reaction to topical fibrin glue. , 1994, Anesthesiology.

[7]  S. Israels,et al.  Development of Antibodies to Bovine and Human Factor V in Two Children After Exposure to Topical Bovine Thrombin , 1994, American Journal Of Pediatric Hematology/Oncology.

[8]  W. Muntean,et al.  Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two‐year‐old child , 1994, Acta paediatrica.

[9]  P. McCarthy,et al.  Fibrin glue in cardiothoracic surgery. , 1993, Transfusion medicine reviews.

[10]  D. Rothenberg,et al.  Anaphylactic reaction to topical bovine thrombin. , 1993, Anesthesiology.

[11]  U. Martinowitz,et al.  Dental extractions in patients with bleeding disorders. The use of fibrin glue. , 1993, Oral surgery, oral medicine, and oral pathology.

[12]  G. Warden,et al.  A prospective study of blood loss with excisional therapy in pediatric burn patients. , 1993, The Journal of trauma.

[13]  B. Brenner,et al.  Circumcision in hemophilia: the use of fibrin glue for local hemostasis. , 1992, The Journal of urology.

[14]  D. Sierra,et al.  Experimental and clinical applications of fibrin glue. , 1991, Plastic and reconstructive surgery.

[15]  K. Tadokoro,et al.  Topical thrombin-induced IgE-mediated anaphylaxis: RAST analysis and skin test studies. , 1991, The Journal of allergy and clinical immunology.

[16]  R Berguer,et al.  Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports. , 1991, The Journal of trauma.

[17]  P. Ness,et al.  Fibrin glue: the perfect operative sealant? , 1990, Transfusion.

[18]  W D Spotnitz,et al.  Neurosurgical applications of fibrin glue: augmentation of dural closure in 134 patients. , 1990, Neurosurgery.

[19]  D. Cosgrove,et al.  Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac operations. A multicenter study. , 1989, The Journal of thoracic and cardiovascular surgery.

[20]  F. Decataldo,et al.  MANAGEMENT OF ORAL BLEEDING IN HAEMOPHILIC PATIENTS , 1988, The Lancet.

[21]  W. Spotnitz,et al.  Application of single-donor fibrin glue to burns. , 1988, The Journal of burn care & rehabilitation.

[22]  M. Hilgartner,et al.  VIRUS SAFETY OF SOLVENT/DETERGENT-TREATED ANTIHAEMOPHILIC FACTOR CONCENTRATE , 1988, The Lancet.

[23]  H. Matras.  The use of fibrin sealant in oral and maxillofacial surgery. , 1982, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[24]  O. Kolar.  SUBACUTE SCLEROSING PANENCEPHALITIS AND SALK VACCINE , 1973 .

[25]  E. Cronkite,et al.  USE OF THROMBIN AND FIBRINOGEN IN SKIN GRAFTING: PRELIMINARY REPORT , 1944 .

[26]  S. Miller,et al.  The hemostatic effect of fibrin glue on graft donor sites. , 1994, The Journal of burn care & rehabilitation.

[27]  G. Sándor,et al.  Face lifts and sprayed fibrin glue: an outcome analysis of 200 patients. , 1994, British journal of plastic surgery.